JP2002507115A - 増大した可溶性発現および/または低下した一酸化窒素の排出を伴うヘモグロビン変異体 - Google Patents
増大した可溶性発現および/または低下した一酸化窒素の排出を伴うヘモグロビン変異体Info
- Publication number
- JP2002507115A JP2002507115A JP54825298A JP54825298A JP2002507115A JP 2002507115 A JP2002507115 A JP 2002507115A JP 54825298 A JP54825298 A JP 54825298A JP 54825298 A JP54825298 A JP 54825298A JP 2002507115 A JP2002507115 A JP 2002507115A
- Authority
- JP
- Japan
- Prior art keywords
- leu
- trp
- val
- phe
- met
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/795—Porphyrin- or corrin-ring-containing peptides
- C07K14/805—Haemoglobins; Myoglobins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.組換え改変ヘモグロビンの高可溶性発現の方法であって、以下の工程: (a)機能的に改変されたヘモグロビンの形成に関与し得るグロビンをコー ドするヌクレオチド配列を含むベクターを宿主細胞に取り込ませる工程であ って、ここで、該ヌクレオチド配列は、少なくとも1つの高可溶性発現変異 、または以下の群より選択される変異の組み合わせを有するβグロビンをコ ードする、工程: D73I; D73M; D73E; D73T; D73K; D73L; K82E; K82G; K82P; K82Q; K82S; K82N; K82H; N102A; N102V K82D(Providence)+D73G(Tilberg);および K82D(Providence)+D73Y(Vancouver); (b)可溶性の組換え改変ヘモグロビンを発現するように宿主細胞を誘導する 工程;ならびに (c)宿主細胞から可溶性の組換え改変ヘモグロビンを精製する工程、 を包含する、方法。 2.以下からなる群より選択されるβグロビン中の変異を含む、組換え改変ヘモ グロビン:D73I、D73M、D73E、D73T、D73K、D73L、K82E、K82G、K82P、K82Q 、K82S、K82N、K82H、N102A、およびN102V。 3.以下からなる群より選択される高可溶性発現変異を含むβグロビンをコード する、組換えDNA分子:D73I、D73M、D73E、D73T、D73K、D73L、K82E、K82G 、K82P、K82Q、K82S、K82N、K82H、N102A、およびN102V。 4.以下からなる群より選択される変異の組み合わせを含む、組換え高可溶性発 現変異ヘモグロビン: βV67W+D73E; βV67W+D73I; βV67W+D73Y(Vancouver); βV67W+D73E+K82D(Providence); βV67W+D73I+K82D(Providence); βV67W+D73Y(Vancouver)+K82D(Providence); βV67W+K82E; βV67W+K82G; βV67F+K82D(Providence)+N108K(Presbyterian); ジαL29F,H58Q/βL106W+K82D(Providence)+N102Y(St.Mande); ジαL29F,H58Q/βL106W+K82D(Providence)+N108K(Presbyterian); ジ-ジαL29F,H58Q/βL106W+K82D(Providence)+N102Y(St.Mande); ジ-ジαL29F,H58Q/βL106W+K82D(Providence)+N108K(Presbyterian); ジαL29F,H58Q/βV67W+K82D(Providence); ジαL29W,H58Q/βV67W+K82D(Providence); ジαL29W,H58Q/βV67W+K82D(Providence)+N108K(Presbyterian); ジ-ジαL29W,H58Q/βV67W+K82D(Providence);および ジ-ジαL29W,H58Q/βV67W+K82D(Providence)+N108K(Presbyterian)。 5.機能的に改変されたヘモグロビンの形成に関与し得るグロビンをコードする 、組換えDNA分子であって、ここで、該DNA分子は、以下からなる群より選択 される変異の組み合わせを有するαおよびβグロビンをコードする、分子: βV67W+D73E; βV67W+D73I; βV67W+D73Y(Vancouver); βV67W+D73E+K82D(Providence); βV67W+D73I+K82D(Providence); βV67W+D73Y(Vancouver)+K82D(Providence); βV67W+K82E; βV67W+K82G; βV67F+K82D(Providence)+N108K(Presbyterian); ジαL29F,H58Q/βL106W+K82D(Providence)+N102Y(St.Mande); ジαL29F,H58Q/βL106W+K82D(Providence)+N108K(Presbyterian); ジ-ジαL29F,H58Q/βL106W+K82D(Providence)+N102Y(St.Mande); ジ-ジαL29F,H58Q/βL106W+K82D(Providence)+N108K(Presbyterian); ジαL29F,H58Q/βV67W+K82D(Providence); ジαL29W,H58Q/βV67W+K82D(Providence); ジαL29W,H58Q/βV67W+K82D(Providence)+N108K(Presbyterian); ジ-ジαL29W,H58Q/βV67W+K82D(Providence);および ジ-ジαL29W,H58Q/βV67W+K82D(Providence)+N108K(Presbyterian)。 6.低下した一酸化窒素との反応速度を有し、以下からなる群より選択されるα グロビン中の変異または変異の組み合わせを含む、組換えヘモグロビン変異 体: E11(Val→Leu)およびE7(His→Gln); E11(Val→Trp)およびE7(His→Gln); E11(Val→PheまたはTrpまたはLeu)およびE7(His→Gln)およびG8(Leu →PheまたはTrp); B10(Leu→Phe)およびE4(Val→Leu); B10(Leu→Trp)およびE4(Val→Leu); B10(Leu→Trp)およびE7(His→Gln); B10(Leu→Phe)およびE7(His→Gln); B10(Leu→Phe)およびE7(His→Gln)およびG8(Leu→Trp); B10(Leu→Trp)およびE11(Val→Phe); B10(Leu→Trp)およびE11(Val→Trp); B10(Leu→Trp)およびE11(Val→Leu)およびG8(Leu→Trp); B10(Leu→Trp)およびE11(Val→Leu)およびG8(Leu→Phe); B10(Leu→Trp)およびE11(Val→Phe)およびG8(Leu→Trp); B10(Leu→Trp)およびE11(Val→Phe)およびG8(Leu→Ile); B10(Leu→Trp)およびE7(His→Gln)およびE11(Val→Leu)およびG8(Le u→Trp); B10(Leu→Trp)およびE11(Val→Trp)およびG8(Leu→Trp); E11(Val→Leu)およびG8(Leu→Phe); E11(Val→Leu)およびG8(Leu→Trp); G12(Leu→PheまたはTrp);ならびに B14(Phe→Trp)。 7.一酸化窒素との低下した反応速度を有し、以下からなる群より選択されるβ グロビン中の変異または変異の組み合わせを含む、組換えヘモグロビン変異 体: E11(Val→Trp)およびG10(Asn→Lys)(Presbyterian); E11(Val→Phe)およびG4(Asn→Tyr)(St.Mande); G8(Leu→Trp)およびG4(Asn→Tyr)(St.Mande)およびEF6(Lys→Asp) (Providence); G8(Leu→Trp)およびEF6(Lys→Asp)(Providence)およびG10(Asn→Lys )(Presbyterian); E11(Val→Trp)およびEF6(Lys→Asp)(Providence); G12(Leu→PheまたはTrp); B10(Leu→Phe)およびE4(Val→Leu); B10(Leu→Trp)およびE4(Val→Leu); B14(Leu→PheまたはTrp); G8(Leu→Phe)およびG12(Leu→Trp); E11(Val→Leu)およびG8(Leu→Trp); E11(Val→Trp)およびG8(Leu→Met); E11(Val→Leu)およびG8(Leu→Phe); E11(Val→Leu)およびG8(Leu→Met); E11(Val→Phe)およびG8(Leu→Ile); E11(Val→Phe)およびG8(Leu→Phe); E11(Val→Phe)およびG8(Leu→Trp); E11(Val→Phe)およびG8(Leu→Met); E11(Val→Met)およびG8(Leu→Trp); E11(Val→Met)およびG8(Leu→Met); E11(Val→Met)およびG8(Leu→Phe); E11(Val→Met)およびG8(Leu→Trp)およびE7(His→Gln); E11(Val→Trp)およびG8(Leu→Ile); E7(His→Tyr)およびG8(Leu→Trp); E7(His→Phe)およびG8(Leu→Trp); E7(His→Gln)およびE11(Val→Trp); E7(His→Tyr)およびE11(Val→Trp); E7(His→Phe)およびE11(Val→Trp); E7(His→Gln)およびE11(Val→Leu); E7(His→Gln)およびE11(Val→Phe)およびG8(Leu→PheまたはTrp); E7(His→Gln)およびE11(Val→Leu、Met、またはTrp)およびG8(Leu→Ph eまたはTrp); E11(Val→TrpまたはPhe)およびG12(Leu→TrpまたはMet); E11(Val→TrpまたはPhe)およびB13(Leu→TrpまたはMet); B10(Leu→Trp)およびB13(Leu→TrpまたはMet); B10(Leu→Phe)およびB13(Leu→Trp); B10(Leu→TrpまたはPhe)およびG12(Leu→Trp); B10(Leu→Phe)およびG12(Leu→Met); G8(Leu→Trp)およびG12(Leu→TrpまたはMet); G8(Leu→Phe)およびG12(Leu→TrpまたはMet); G8(Leu→Trp)およびB13(Leu→TrpまたはMet);ならびに G8(Leu→Phe)およびB3(Leu→TrpまたはMet)。 8.以下からなる群より選択される変異の組み合わせを含む、組換えヘモグロビ ン変異体: αB10(Leu→Trp)、αE7(His→Gln)およびβE11(Val→Trp);ならびに αB10(Leu→Phe)、αE7(His→Gln)およびβG8(Leu→Trp)。 9.以下からなる群より選択される変異または変異の組み合わせを含むαグロビ ンをコードする、組換えDNA分子: E11(Val→Leu)およびE7(His→Gln); E11(Val→Trp)およびE7(His→Gln); E11(Val→PheまたはTrpまたはLeu)およびE7(His→Gln)およびG8(Leu→ PheまたはTrp); B10(Leu→Phe)およびE4(Val→Leu); B10(Leu→Trp)およびE4(Val→Leu); B10(Leu→Trp)およびE7(His→Gln); B10(Leu→Phe)およびE7(His→Gln); B10(Leu→Phe)およびE7(His→Gln)およびG8(Leu→Trp); B10(Leu→Trp)およびE11(Val→Phe); B10(Leu→Trp)およびE11(Val→Trp); B10(Leu→Trp)およびE11(Val→Leu)およびG8(Leu→Trp); B10(Leu→Trp)およびE11(Val→Leu)およびG8(Leu→Phe); B10(Leu→Trp)およびE11(Val→Phe)およびG8(Leu→Trp); B10(Leu→Trp)およびE11(Val→Phe)およびG8(Leu→Ile); B10(Leu→Trp)およびE7(His→Gln)およびE11(Val→Leu)およびG8(Le u→Trp); B10(Leu→Trp)およびE11(Val→Trp)およびG8(Leu→Trp); E11(Val→Leu)およびG8(Leu→Phe); E11(Val→Leu)およびG8(Leu→Trp); G12(Leu→PheまたはTrp);ならびに B14(Phe→Trp)。 10.以下からなる群より選択される変異または変異の組み合わせを含むβグロ ビンをコードする、組換えDNA分子: E11(Val→Trp)およびG10(Asn→Lys)(Presbyterian); E11(Val→Phe)およびG4(Asn→Tyr)(St.Mande); G8(Leu→Trp)およびG4(Asn→Tyr)(St.Mande)およびEF6(Lys→Asp) (Providence); G8(Leu→Trp)およびEF6(Lys→Asp)(Providence)およびG10(Asn→Lys )(Presbyterian); E11(Val→Trp)およびEF6(Lys→Asp)(Providence); G12(Leu→PheまたはTrp); B10(Leu→Phe)およびE4(Val→Leu); B10(Leu→Trp)およびE4(Val→Leu); B14(Leu→PheまたはTrp); G8(Leu→Phe)およびG12(Leu→Trp); E11(Val→Leu)およびG8(Leu→Trp); E11(Val→Trp)およびG8(Leu→Met); E11(Val→Leu)およびG8(Leu→Phe); E11(Val→Leu)およびG8(Leu→Met); E11(Val→Phe)およびG8(Leu→Ile); E11(Val→Phe)およびG8(Leu→Phe); E11(Val→Phe)およびG8(Leu→Trp); E11(Val→Phe)およびG8(Leu→Met); E11(Val→Met)およびG8(Leu→Trp); E11(Val→Met)およびG8(Leu→Met); E11(Val→Met)およびG8(Leu→Phe); E11(Val→Met)およびG8(Leu→Trp)およびE7(His→Gln); E11(Val→Trp)およびG8(Leu→Ile); E7(His→Tyr)およびG8(Leu→Trp); E7(His→Phe)およびG8(Leu→Trp); E7(His→Gln)およびE11(Val→Trp); E7(His→Tyr)およびE11(Val→Trp); E7(His→Phe)およびE11(Val→Trp); E7(His→Gln)およびE11(Val→Leu); E7(His→Gln)およびE11(Val→Phe)およびG8(Leu→PheまたはTrp); E7(His→Gln)およびE11(Val→Leu、Met、またはTrp)およびG8(Leu→Ph eまたはTrp); E11(Val→TrpまたはPhe)およびG12(Leu→TrpまたはMet); E11(Val→TrpまたはPhe)およびB13(Leu→TrpまたはMet); B10(Leu→Trp)およびB13(Leu→TrpまたはMet); B10(Leu→Phe)およびB13(Leu→Trp); B10(Leu→TrpまたはPhe)およびG12(Leu→Trp); B10(Leu→Phe)およびG12(Leu→Met); G8(Leu→Trp)およびG12(Leu→TrpまたはMet); G8(Leu→Phe)およびG12(Leu→TrpまたはMet); G8(Leu→Trp)およびB13(Leu→TrpまたはMet);ならびに G8(Leu→Phe)およびB13(Leu→TrpまたはMet)。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US4536497P | 1997-05-02 | 1997-05-02 | |
US60/045,364 | 1997-05-02 | ||
US5798697P | 1997-09-05 | 1997-09-05 | |
US60/057,986 | 1997-09-05 | ||
PCT/US1998/008861 WO1998050430A2 (en) | 1997-05-02 | 1998-05-01 | Hemoglobin mutants with increased soluble expression and/or reduced nitric oxide scavenging |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008094054A Division JP4399634B2 (ja) | 1997-05-02 | 2008-03-31 | 増大した可溶性発現および/または低下した一酸化窒素の排出を伴うヘモグロビン変異体 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2002507115A true JP2002507115A (ja) | 2002-03-05 |
JP2002507115A5 JP2002507115A5 (ja) | 2006-03-02 |
JP4512673B2 JP4512673B2 (ja) | 2010-07-28 |
Family
ID=26722688
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP54825298A Expired - Fee Related JP4512673B2 (ja) | 1997-05-02 | 1998-05-01 | 増大した可溶性発現および/または低下した一酸化窒素の排出を伴うヘモグロビン変異体 |
JP2008094054A Expired - Fee Related JP4399634B2 (ja) | 1997-05-02 | 2008-03-31 | 増大した可溶性発現および/または低下した一酸化窒素の排出を伴うヘモグロビン変異体 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008094054A Expired - Fee Related JP4399634B2 (ja) | 1997-05-02 | 2008-03-31 | 増大した可溶性発現および/または低下した一酸化窒素の排出を伴うヘモグロビン変異体 |
Country Status (7)
Country | Link |
---|---|
US (2) | US6455676B1 (ja) |
EP (1) | EP0979279B1 (ja) |
JP (2) | JP4512673B2 (ja) |
AU (1) | AU750295B2 (ja) |
CA (1) | CA2299049C (ja) |
DE (1) | DE69839263T2 (ja) |
WO (1) | WO1998050430A2 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2014532764A (ja) * | 2011-11-07 | 2014-12-08 | ザ ジェネラル ホスピタル コーポレイション | 赤血球の処理法 |
JP2022515560A (ja) * | 2019-02-01 | 2022-02-18 | チアー グローバル リミテッド | 組み換えヘモグロビン、その製造方法およびその使用 |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6670323B1 (en) | 1999-11-12 | 2003-12-30 | Baxter International, Inc. | Reduced side-effect hemoglobin compositions |
EP1463440B1 (en) * | 2001-12-06 | 2009-12-02 | Duke University | Prevention of flap necrosis in plastic surgery |
DE10224750A1 (de) | 2002-06-04 | 2003-12-24 | Fresenius Medical Care De Gmbh | Vorrichtung zur Behandlung einer medizinischen Flüssigkeit |
US7642233B2 (en) * | 2004-09-15 | 2010-01-05 | William Marsh Rice University | Enhancing recombinant hemoglobin production by co-expression with alpha hemoglobin stabilizing protein |
WO2006031992A2 (en) * | 2004-09-15 | 2006-03-23 | William Marsh Rice University | Increasing hemoglobin and other heme protein production in bacteria by co-expression of heme transport genes |
US20070166792A1 (en) * | 2004-09-15 | 2007-07-19 | Olson John S | Increasing hemoglobin and other heme protein production in bacteria by co-expression of heme transport genes |
US7935074B2 (en) | 2005-02-28 | 2011-05-03 | Fresenius Medical Care Holdings, Inc. | Cassette system for peritoneal dialysis machine |
US20060195064A1 (en) * | 2005-02-28 | 2006-08-31 | Fresenius Medical Care Holdings, Inc. | Portable apparatus for peritoneal dialysis therapy |
US8197231B2 (en) | 2005-07-13 | 2012-06-12 | Purity Solutions Llc | Diaphragm pump and related methods |
US9127208B2 (en) * | 2006-04-03 | 2015-09-08 | Pharmatherm Chemicals, Inc. | Thermal extraction method and product |
DK2040740T3 (en) | 2006-05-22 | 2014-12-01 | Univ California | COMPOSITIONS AND PROCEDURES FOR DELIVERING NITROGEN MONOXIDE |
US7905990B2 (en) | 2007-11-20 | 2011-03-15 | Ensyn Renewables, Inc. | Rapid thermal conversion of biomass |
US8192401B2 (en) | 2009-03-20 | 2012-06-05 | Fresenius Medical Care Holdings, Inc. | Medical fluid pump systems and related components and methods |
CA2767668C (en) | 2009-07-15 | 2017-03-07 | Fresenius Medical Care Holdings, Inc. | Medical fluid cassettes and related systems and methods |
US8720913B2 (en) * | 2009-08-11 | 2014-05-13 | Fresenius Medical Care Holdings, Inc. | Portable peritoneal dialysis carts and related systems |
US8499702B2 (en) | 2010-07-15 | 2013-08-06 | Ensyn Renewables, Inc. | Char-handling processes in a pyrolysis system |
DE102010053973A1 (de) | 2010-12-09 | 2012-06-14 | Fresenius Medical Care Deutschland Gmbh | Medizinisches Gerät mit einer Heizung |
WO2012087798A2 (en) | 2010-12-20 | 2012-06-28 | Fresenius Medical Care Holdings, Inc. | Medical fluid cassettes and related systems and methods |
US9624915B2 (en) | 2011-03-09 | 2017-04-18 | Fresenius Medical Care Holdings, Inc. | Medical fluid delivery sets and related systems and methods |
WO2012154352A1 (en) | 2011-04-21 | 2012-11-15 | Fresenius Medical Care Holdings, Inc. | Medical fluid pumping systems and related devices and methods |
US9186449B2 (en) | 2011-11-01 | 2015-11-17 | Fresenius Medical Care Holdings, Inc. | Dialysis machine support assemblies and related systems and methods |
US9109177B2 (en) | 2011-12-12 | 2015-08-18 | Ensyn Renewables, Inc. | Systems and methods for renewable fuel |
US9610392B2 (en) | 2012-06-08 | 2017-04-04 | Fresenius Medical Care Holdings, Inc. | Medical fluid cassettes and related systems and methods |
US9500188B2 (en) | 2012-06-11 | 2016-11-22 | Fresenius Medical Care Holdings, Inc. | Medical fluid cassettes and related systems and methods |
FR3002146B1 (fr) * | 2013-02-15 | 2016-03-04 | Hemarina | Utilisation d'hemoglobine d'annelides pour traiter les cancers |
US9561323B2 (en) | 2013-03-14 | 2017-02-07 | Fresenius Medical Care Holdings, Inc. | Medical fluid cassette leak detection methods and devices |
US10117985B2 (en) | 2013-08-21 | 2018-11-06 | Fresenius Medical Care Holdings, Inc. | Determining a volume of medical fluid pumped into or out of a medical fluid cassette |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8711614D0 (en) * | 1987-05-16 | 1987-06-24 | Medical Res Council | Proteins |
US5449759A (en) | 1987-05-16 | 1995-09-12 | Somatogen, Inc. | Hemoglobins with intersubunit desulfide bonds |
US6022849A (en) * | 1987-05-16 | 2000-02-08 | Baxter Biotech Technology Saarl | Mutant recombinant hemoglobins containing heme pocket mutations |
US5844090A (en) | 1994-05-09 | 1998-12-01 | Somatogen, Inc. | Modified hemoglobin-like compounds |
US5599907A (en) | 1989-05-10 | 1997-02-04 | Somatogen, Inc. | Production and use of multimeric hemoglobins |
US5545727A (en) | 1989-05-10 | 1996-08-13 | Somatogen, Inc. | DNA encoding fused di-alpha globins and production of pseudotetrameric hemoglobin |
US5173426A (en) * | 1989-10-06 | 1992-12-22 | Yale University | DNAs encoding genetically engineered low oxygen affinity mutants of human hemoglobin |
JPH09506332A (ja) | 1993-09-14 | 1997-06-24 | メディカル リサーチ カウンセル | ヘモグロビンの改良またはヘモグロビンに関する改良 |
US5665869A (en) | 1993-11-15 | 1997-09-09 | Somatogen, Inc. | Method for the rapid removal of protoporphyrin from protoporphyrin IX-containing solutions of hemoglobin |
US5843888A (en) * | 1995-05-01 | 1998-12-01 | Carnegie Mellon University | Low oxygen affinity mutant hemoglobin |
WO1997004110A1 (en) * | 1995-07-14 | 1997-02-06 | Somatogen, Inc. | Methods for increasing protein expression |
JPH11514237A (ja) * | 1995-10-23 | 1999-12-07 | ライス ユニバーシティ | ヘム損失を減少させるヘモグロビン変異体 |
WO1997023631A2 (en) | 1995-12-22 | 1997-07-03 | Somatogen, Inc. | Globins containing binding domains |
-
1998
- 1998-05-01 JP JP54825298A patent/JP4512673B2/ja not_active Expired - Fee Related
- 1998-05-01 US US09/403,208 patent/US6455676B1/en not_active Expired - Fee Related
- 1998-05-01 CA CA002299049A patent/CA2299049C/en not_active Expired - Fee Related
- 1998-05-01 EP EP98920113A patent/EP0979279B1/en not_active Expired - Lifetime
- 1998-05-01 DE DE69839263T patent/DE69839263T2/de not_active Expired - Lifetime
- 1998-05-01 WO PCT/US1998/008861 patent/WO1998050430A2/en active IP Right Grant
- 1998-05-01 AU AU72758/98A patent/AU750295B2/en not_active Ceased
-
2002
- 2002-03-27 US US10/107,871 patent/US7049406B2/en not_active Expired - Fee Related
-
2008
- 2008-03-31 JP JP2008094054A patent/JP4399634B2/ja not_active Expired - Fee Related
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2014532764A (ja) * | 2011-11-07 | 2014-12-08 | ザ ジェネラル ホスピタル コーポレイション | 赤血球の処理法 |
JP2022515560A (ja) * | 2019-02-01 | 2022-02-18 | チアー グローバル リミテッド | 組み換えヘモグロビン、その製造方法およびその使用 |
JP7066067B2 (ja) | 2019-02-01 | 2022-05-12 | チアー グローバル リミテッド | 組み換えヘモグロビン、その製造方法およびその使用 |
Also Published As
Publication number | Publication date |
---|---|
WO1998050430A2 (en) | 1998-11-12 |
JP4512673B2 (ja) | 2010-07-28 |
CA2299049C (en) | 2008-07-15 |
EP0979279A2 (en) | 2000-02-16 |
DE69839263T2 (de) | 2009-04-30 |
JP2008194051A (ja) | 2008-08-28 |
JP4399634B2 (ja) | 2010-01-20 |
AU7275898A (en) | 1998-11-27 |
US6455676B1 (en) | 2002-09-24 |
US7049406B2 (en) | 2006-05-23 |
WO1998050430A3 (en) | 1999-04-01 |
AU750295B2 (en) | 2002-07-11 |
DE69839263D1 (de) | 2008-04-30 |
CA2299049A1 (en) | 1998-11-12 |
EP0979279B1 (en) | 2008-03-19 |
US20030017537A1 (en) | 2003-01-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2002507115A (ja) | 増大した可溶性発現および/または低下した一酸化窒素の排出を伴うヘモグロビン変異体 | |
AU784195B2 (en) | Reduced side-effect hemoglobin compositions | |
AU672960B2 (en) | Production and use of multimeric hemoglobins | |
US6184356B1 (en) | Production and use of multimeric hemoglobins | |
JP3991057B2 (ja) | 改変ヘモグロビン化合物およびその精製方法 | |
US6218513B1 (en) | Globins containing binding domains | |
JPH11514237A (ja) | ヘム損失を減少させるヘモグロビン変異体 | |
JPH09500639A (ja) | ニッケルを含まないヘモグロビンおよびこのようなヘモグロビンを生産するための方法 | |
WO1997023631A2 (en) | Globins containing binding domains | |
EP0784983A2 (en) | Use of extracellular hemoglobin | |
EP1950298A2 (en) | Hemoglobin mutants with increased soluble expression and/or reduced nitric oxide scavenging | |
US6150506A (en) | Modified hemoglobin-like compounds and methods of purifying same | |
CA2618690A1 (en) | Hemoglobin mutants with increased soluble expression and/or reduced nitric oxide scavenging | |
JP2000516455A (ja) | ヘモグロビンにおけるβダイマー形成を制御する方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050215 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050927 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20071030 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080129 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080310 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080228 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080414 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080331 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080520 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080813 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080929 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080919 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20081111 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090206 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20090414 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20090514 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20090513 |
|
A72 | Notification of change in name of applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A721 Effective date: 20090513 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130521 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130521 Year of fee payment: 3 |
|
R370 | Written measure of declining of transfer procedure |
Free format text: JAPANESE INTERMEDIATE CODE: R370 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130521 Year of fee payment: 3 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313117 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130521 Year of fee payment: 3 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |